RAN-QUINAPRIL TABLET

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE)

Beszerezhető a:

RANBAXY PHARMACEUTICALS CANADA INC.

ATC-kód:

C09AA06

INN (nemzetközi neve):

QUINAPRIL

Adagolás:

40MG

Gyógyszerészeti forma:

TABLET

Összetétel:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 40MG

Az alkalmazás módja:

ORAL

db csomag:

30/1000

Recept típusa:

Prescription

Terápiás terület:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Termék összefoglaló:

Active ingredient group (AIG) number: 0123206004; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2014-10-17

Termékjellemzők

_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
RAN
™
-QUINAPRIL
QUINAPRIL TABLETS USP
(5 MG, 10 MG, 20 MG AND 40 MG OF QUINAPRIL AS QUINAPRIL HYDROCHLORIDE)
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, ON
L6T 1C1
Date of Revision:
June 22, 2017
CONTROL NO. 206533
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
15
DOSAGE AND ADMINISTRATION
................................................................................
18
OVERDOSAGE
...................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION ANDPACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
24
PHARMACEUTICAL INFORMATION
......................